

Everest Medicines partners with Guangdong Academy of Medical Sciences for renal diseases research

24 March 2023 | News

Everest Medicines' innovative drug candidates in renal space include Nefecon, the first-in-disease therapy for the treatment of primary immunoglobulin A nephropathy (IgAN)



China-based startup Everest Medicines, has signed a Memorandum of Understanding (MoU) for comprehensive strategic cooperation with Guangdong Academy of Medical Sciences in renal disease research, scientific innovation and translational studies.

The signing ceremony was held at the opening ceremony of Guangdong Medical Technology Week. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, and Professor Yu Xueqing, President of Guangdong Academy of Medical Sciences attended the ceremony.

Professor Yu Xueqing is an internationally renowned nephrologist who has held positions including President of International Society for Peritoneal Dialysis, Executive Director of the International Society of Nephrology, Chairman of the Chinese Society of Nephrology and is the president-elect of the Asia-Pacific Society of Nephrology.

Strategically situated in the Greater Bay Area and aligned with the implementation of key projects such as the development of national and regional medical centers, the Academy of Medical Sciences has a scientific research team to carry out R&D on critical and chronic non-infectious diseases and strives to advance research results into clinical development as soon as possible.

Everest Medicines' innovative drug candidates in renal space include Nefecon, the first-in-disease therapy for the treatment of primary immunoglobulin A nephropathy (IgAN). The China National Medical Products Administration (NMPA) accepted the New Drug Application (NDA) for Nefecon in November 2022 and has also granted break-through therapy designation and priority review. In addition, EVER001, a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor, is in clinical development for the treatment of glomerular diseases. The company also has several programmes at discovery stage with the most advanced candidate expected to file an IND next year.